Know Cancer

forgot password

Cyclophosphamide, Doxorubicin, Vincristine, Prednisone Plus Rituximab (CHOP-R) and Cyclophosphamide, Pixantrone, Vincristine, Prednisone Plus Rituximab (CPOP-R) in Patients With Diffuse Large-B-cell Lymphoma: A Phase II, Randomized, Multicenter, Comparative Trial

Phase 2
18 Years
Not Enrolling
Diffuse Large-Cell Lymphoma

Thank you

Trial Information

Cyclophosphamide, Doxorubicin, Vincristine, Prednisone Plus Rituximab (CHOP-R) and Cyclophosphamide, Pixantrone, Vincristine, Prednisone Plus Rituximab (CPOP-R) in Patients With Diffuse Large-B-cell Lymphoma: A Phase II, Randomized, Multicenter, Comparative Trial

In preclinical studies, pixantrone has shown significantly less cardiotoxicity than other
anthracyclines or anthracenediones. In addition, patients with relapsed disease, who have
received prior maximum doses of anthracyclines, have tolerated high doses of pixantrone with
minimal added cardiotoxicity. Pixantrone is currently being studied in a Phase III study in
3rd line aggressive NHL.

Inclusion Criteria:

1. Previously untreated and histologically confirmed diffuse large B-cell lymphoma
according to REAL/WHO classification.

2. Stage II, III or IV disease

3. CD20+

4. Age ≥ 18 years

5. ECOG performance status ≤ 2

6. At least one objectively bidimensionally measurable lesion as demonstrated by CT,
spiral CT, or MRI that can be followed for response as target lesion. Patients with
the following sites of disease are NOT eligible:

- Patients with only skin lesions or only palpable lymph nodes.

- Patients with spleen or bone marrow as only site of disease.

7. Life expectancy ≥ 3 months

8. Serum bilirubin ≤ 1.5 x the institution's upper limit normal (ULN) and creatinine ≤
2.0 ULN and AST or ALT ≤ 2.0 x the institution's ULN. If hepatic involvement by
lymphoma is present, AST or ALT may be ≤ 5.0 x the institution's ULN.

9. LVEF ≥ 50% determined by MUGA scan.

10. Ability to comply with the visit schedule and assessments required by the protocol.

11. Signed approved informed consent, with understanding of study procedures.

Exclusion Criteria:

1. Any prior chemotherapy (except intrathecal chemotherapy at diagnosis and pretreatment
corticosteroid therapy) or radiotherapy: Patients may receive corticosteroid
pretreatment therapy for up to 7 days after randomization, pending Investigator's
decision to reduce tumor burden.

2. Histological diagnosis of T-cell lymphoma or any B-cell lymphoma other than diffuse
large B-cell.

3. History of indolent lymphoma

4. Active CNS involvement based on clinical evaluation .

5. HIV-related lymphoma.

6. Major thoracic and/or abdominal surgery within the 4 weeks before randomization from
which the patient has not fully recovered except for diagnosis of NHL. Patients who
have had minor surgery may be enrolled after a ≥ 1 week recovery period except for
diagnosis of NHL.

7. Clinically significant cardiovascular abnormalities

8. Serious (NCI CTCAE grade 3-4) intercurrent infection at randomization or deep seated
or systemic mycotic infections.

9. Clinical symptoms suggesting unresolved HIV, HBV or HCV infection. Patients with
seropositivity presumed to be due to prior vaccination against Hepatitis B virus or
resolved infection will not be excluded.

10. Active or history of another malignancy except cured basal cell carcinoma of skin or
carcinoma in situ of uterine cervix. Patients who have been in remission from another
previous malignancy for >5 years will be considered eligible.

11. Known hypersensitivity to the excipients or the study drugs that the patient will

12. Any contraindications to the study drugs as described in the Summary of Product
Characteristics or package inserts. 13. Neurological contraindication to vincristine
(e.g. peripheral neuropathy).

14. Any condition which, in the judgment of the Investigator, would place the subject at
undue risk, interfere with the results of the study, or make the subject otherwise
unsuitable. 15. General status that, in the opinion of the Investigator does not permit
the administration of eight courses of CHOP-R/CPOP-R. 16. Treatment with any other
investigational study drug within 30 days before randomization. Patient must have
recovered from all side effects of other investigational therapy. 17. Potentially fertile
men and women and their sexual partners not willing to use adequate contraception as
defined by the Investigator during the study and for 6 months after the last day of study
drug administration.

18. Any circumstance at the time of study entry that would preclude completion of the
study or the required follow-up.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

The primary objective is to show that the response rate for CPOP-R is not inferior to that of CHOP-R.

Outcome Time Frame:

Subjects followed for 5 years post treatment

Safety Issue:


Principal Investigator

Gabor Jurida, M.D.

Investigator Role:

Study Director

Investigator Affiliation:

Cell Therapeutics


United States: Food and Drug Administration

Study ID:




Start Date:

November 2005

Completion Date:

May 2012

Related Keywords:

  • Diffuse Large-Cell Lymphoma
  • lymphoma
  • NHL
  • large cell
  • phase II
  • CHOP R
  • CPOP R
  • non Hodgkins
  • Lymphoma
  • Lymphoma, Large B-Cell, Diffuse
  • Lymphoma, Non-Hodgkin
  • Lymphoma, B-Cell



Loma Linda University Medical CenterLoma Linda, California  92354
Thompson Cancer Survival CenterKnoxville, Tennessee  37916
Southwest Regional Cancer CenterAustin, Texas  78705
Rocky Mountain Cancer CenterDenver, Colorado  80218
Our Lady of Mercy Medical CenterBronx, New York  10466
John B. Amos Cancer CenterColumbus, Georgia  31904
Consultants in Blood Disorders and CancerLouisville, Kentucky  40207
Watson ClinicLakeland, Florida  33805
Sharp Memorial HospitalSan Diego, California  92123
Greater Baltimore Medical CenterBaltimore, Maryland  21204
Duke University Medical CenterDurham, North Carolina  27710
Osceola Cancer CenterKissimmee, Florida  34741
Charleston Cancer CenterCharleston, South Carolina  29406
Broward Oncology AssociatesFt. Lauderdale, Florida  33308
Sarah Cannon Cancer CenterNashville, Tennessee  37203
Oncology Partners NetworkCincinnati, Ohio  45238
Dayton Clinical Oncology ProgramDayton, Ohio  45420
The Center for Cancer and Blood DisordersFort Worth, Texas  76104
Hematology Oncology Associates of the Treasure CoastPort St. Lucie, Florida  34952
Western Kentucky Hematology/Oncology GroupPaducah, Kentucky  42003
Nevada Cancer InstituteLas Vegas, Nevada  89135
The Family Cancer CenterCollierville, Tennessee  38017
Watson Clinic for Cancer Care and ResearchLakeland, Florida  33805
Northwest Kaiser PermanentePortland, Oregon  97227
Northern Utah Hematology Oncology, P.C.Ogden, Utah  84403
Maryland Hematology/Oncology Associates, PABaltimore, Maryland  21236
Center for Cancer and Blood Disorders, P.C.Bethesda, Maryland  20817-7847
Hubert H Humphrey Cancer CenterRobbinsdale, Minnesota  55422
Hematology/Oncology Group of Orange CountyOrange, California  92868
Bay Medical Oncology & HematologyConcord, California  94520
Hazel Hawkins Hospital, Dept. of Medical OncologyHollister, California  95020
UCSD Moore's Cancer Center-Blood & Marrow Transplantation DivisionLa Jolla, California  92093
The Center of Hematology and OncologyBoca Raton, Florida  33486
Memorial Cancer InstitutePembroke Pines, Florida  33028
Oncology Hematology Associates of West BrowardTamarac, Florida  33321
Hematology Oncology SpecialistsTampa, Florida  33607
Columbus ClinicColumbus, Georgia  39101
Oncology Hematology of Northern IllinoisGurnee, Illinois  60031
Mid-Illinois Hematology & Oncology AssociatesNormal, Illinois  61761
Our Lady of the Lake Regional Medial Center, Hematology OncologyBaton Rouge, Louisiana  70808
Frederick Memorial Hospital Cancer CenterFrederick, Maryland  21701
Tufts-New England Medical Center-The Neely Ctr for Clinical Cancer ResearchBoston, Massachusetts  02111
North Missssppi Hematology Oncology AssociatesTupelo, Mississippi  38801
Capital Comprehensive Cancer CareJefferson City, Missouri  65109
Southeast Nebraska Hematology and Oncology Consultants, P.C.Lincoln, Nebraska  68510
New Mexico Hematology/Oncology ConsultantsAlbuquerque, New Mexico  87109
Jacobi Medical Center Phase I OncologyBronx, New York  10461
Cancer Care CenterNew Albany, New York  47150
St. Luke's Roosevelt HospitalNew York City, New York  10019
Interlake Foundation, Inc.Rochester, New York  14623
Brody School of Medicine at East Carolina University - Leo W. Jenkins Cancer CenterGreenville, North Carolina  27858
Cancer Treatment & Research Mid-Dakota ClinicBismark, North Dakota  58501
Summa Health Systems HospitalsAkron, Ohio  44304
Barberton Citizen's HospitalBarberton, Ohio  44203
Berks Hematology-Oncology Associates Ltd.Reading, Pennsylvania  19612
Low County Hematology & OncologyMount Pleasant, South Carolina  29464
Texas Hematology Oncology CenterDallas, Texas  75234
Multicare Oncology Hematology SpecialistsTacoma, Washington  98405